Cancer Family
Secondary Neoplasm
CI-CAN-00000050Explore in graph →
Non-malignant4,276 active trials56 approved drugs532 evidence items
- NCIt
- C36255
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000050Explore in graph →
Clinical trials
14,676 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07482059 | A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 33 | West China HospitalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480213 | Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)(DART-NK-SCLC) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480928 | Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma(DUAL-NK-PDAC) | recruiting | Phase 1 / Phase 2 | 42 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03384238 | Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery | recruiting | Phase 1 / Phase 2 | 27 | George PoultsidesOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05746208 | Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors | recruiting | Phase 2 | 29 | University of California, San FranciscoOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05528952 | Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma(TERTIO) | recruiting | Phase 2 | 105 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06756074 | Reinforced Pancreaticojejunostomy With or Without glubran2 | recruiting | Phase 2 | 100 | Minia UniversityOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07052253 | A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. | recruiting | Phase 2 | 100 | AkesoINDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05901519 | A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma | recruiting | Phase 2 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06030440 | De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck(DIREKHT2) | recruiting | Phase 2 / Phase 3 | 508 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06173362 | Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer | recruiting | Phase 2 | 75 | University of California, DavisOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06157827 | A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma | recruiting | Phase 1 / Phase 2 | 178 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07468630 | Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma(TRIUNITE-08) | recruiting | Phase 2 | 106 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06681220 | Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC(Relapsed SCLC) | recruiting | Phase 1 / Phase 2 | 166 | VA Office of Research and DevelopmentFED | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07035249 | DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 9 | West China HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07457528 | Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC | recruiting | Phase 2 | 46 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06223659 | EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers | recruiting | Phase 2 | 100 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07462650 | Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 48 | Beijing BiotechINDUSTRY | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06330805 | Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer | recruiting | Phase 2 | 70 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07391813 | SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer(SNB-101-101) | recruiting | Phase 1 / Phase 2 | 55 | SN BioScienceINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07457359 | Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer(NEOTRIO-2) | recruiting | Phase 2 | 18 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06895031 | Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS(STAR) | recruiting | Phase 2 | 210 | Guangzhou JOYO Pharma Co., LtdINDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05068232 | Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES) | recruiting | Phase 2 | 49 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06318897 | Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer | recruiting | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06530251 | A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) | recruiting | Phase 1 / Phase 2 | 280 | AkesoINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06699602 | A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma | recruiting | Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04988074 | Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca(MINIMA) | recruiting | Phase 2 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06218420 | Evaluation of Stereotactic Body Radiotherapy as a Bridge Therapy for Hepatocellular Carcinoma Patients Enlisted for Liver Transplantation(TRANSRAD-01) | recruiting | Phase 2 | 139 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06461910 | Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 2 | 30 | Zekuan XuOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06719700 | Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer | recruiting | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07446452 | Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study | recruiting | Phase 2 | 37 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT05325632 | Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab | recruiting | Phase 2 | 53 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT06369155 | Azenosertib in Uterine Serous Carcinoma: Biomarker Study | recruiting | Phase 2 | 25 | Joyce Liu, MDOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07223541 | Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma(LAG-BOOST) | recruiting | Phase 2 | 72 | University of OklahomaOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07342283 | QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer | recruiting | Phase 2 | 30 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03808337 | Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease | recruiting | Phase 2 | 145 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06789848 | Ligufalimab and Cadonilimab in Advanced Liver Cancers | recruiting | Phase 2 | 64 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07039162 | Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 45 | Ming-Yu LienOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07044635 | Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.(RAD RAPTORS) | recruiting | Phase 2 | 42 | University of UtahOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07110103 | Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC(JACKPOT38) | recruiting | Phase 2 | 20 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07282834 | Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)(Charlie-2) | recruiting | Phase 2 | 200 | Patrick Wagner, MD, FACSOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07435376 | Intra-lesional Tumor Boost for Bulky Cervical Cancer(INTLECTUAL) | recruiting | Phase 2 | 17 | Seoul National University Bundang HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07435454 | Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 22 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07437898 | Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study | recruiting | Phase 2 | 42 | The Affiliated Hospital of Putian UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07441174 | IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 92 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04134559 | Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma | recruiting | Phase 2 | 18 | Allison O'Neill, MDOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06016387 | Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study | recruiting | Phase 2 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07285057 | Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance | recruiting | Phase 2 | 120 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Feb 23, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Mar 19, 2026source: clinicaltrials